- Home
- HERZ vs TVRD Comparison
HERZ vs TVRD Comparison
Compare HERZ & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HERZ | TVRD |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8M | 27.5M |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HERZ | TVRD |
|---|---|---|
| Price | $15.85 | $1.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 22.0K | ★ 248.9K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $1.62 | $1.50 |
| 52 Week High | $19.30 | $43.65 |
Technical Indicators
Market Signals| Indicator | HERZ | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 45.51 | 39.30 |
| Support Level | $15.27 | $1.70 |
| Resistance Level | $16.45 | $2.04 |
| Average True Range (ATR) | 0.44 | 0.11 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 19.67 | 35.29 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.